Australian and Kiwi startups in fields as diverse as cell therapy, wastewater treatment, and local government software raised ...
With help from the oversubscribed financing round, the Australian firm is eyeing early 2025 for a Phase I clinical trial of its TAG-72-targeting cell therapy.
Immunotherapy company Cartherics Pty Ltd. raised AU$15 million (US$10.3 million) in an oversubscribed series B round that will support the first clinical trial for lead chimeric antigen receptor ...
The latest funding will support the first clinical trial for CTH-401, the startup’s lead cell therapy product, to treat ovarian cancer.
A much-anticipated new treatment for ovarian cancer discovered in Melbourne is also being explored for other conditions ...
Melbourne, Australia, 1 October 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer and other diseases, is ...